Organon & Co. (OGN) intrinsic value & 10-year financials
Organon & Co. (OGN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue shrank 3.7% a year to $6.2B, with an average return on invested capital of 21.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $13.76
- Market cap
- $3.6B
- Revenue (FY2025)
- $6.2B
- Revenue growth (8-yr CAGR)
- -3.7%
- ROIC (10-yr avg)
- 21.0%
- Free cash flow (FY2025)
- $538.0M
OGN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $6.2B | $187.0M | $0.72 | $538.0M | — | 2.1% |
| FY2024 | $6.4B | $864.0M | $3.33 | $764.0M | — | 10.2% |
| FY2023 | $6.3B | $1.0B | $3.99 | $548.0M | — | 13.1% |
| FY2022 | $6.2B | $917.0M | $3.59 | $662.0M | — | 12.6% |
| FY2021 | $6.3B | $1.4B | $5.31 | $2.0B | — | 21.5% |
| FY2020 | $6.5B | $2.2B | $8.52 | $2.0B | — | 39.3% |
| FY2019 | $7.8B | $3.2B | $12.69 | $2.9B | — | 48.1% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Organon & Co. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Organon & Co. has earned high returns on invested capital, averaging 21.0% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Organon & Co. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Organon & Co. is modeled at -38.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-41.94 per share.